Page 42 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $2.11
52wk Low $0.35 Ocugen, Inc. OCGN $1.57
263 Great Valley Parkway
Malvern, PA 19355

(USD - in millions) www.ocugen.com
Market Cap 438.6
Enterprise 391.6
Basic Shares Out. 256.50 COMPANY OVERVIEW
Float 252.38
Institutional Holdings 10.34% Detailed Analysis:Channelchek.com
Short Interest 43.48
Avg. 90-Day Volume 8.70 Ocugen, Inc. is a biotechnology company focused on discovering,
developing, and commercializing novel gene and cell therapies,
biologics, and vaccines that improve health and offer hope for patients
across the globe. We are making an impact on patient’s lives through
EPS Data courageous innovation—forging new scientific paths that harness our
unique intellectual and human capital. Our breakthrough modifier gene
2021 2022 2023 therapy platform has the potential to treat multiple retinal diseases with
CQ1 (0.04) (0.09) (0.07) a single product, and we are advancing research in infectious diseases
CQ2 (0.13) (0.09) (0.10) to support public health and orthopedic diseases to address unmet
medical needs.
CQ3 (0.05) (0.10) (0.06)
CQ4 (0.07) (0.10) (0.06)
CY (0.30) (0.38) (0.28) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.23
ROE (ttm) -98.28
Debt-to-Total Cap. (mrq) 9.98
Fiscal Year End 31-Dec

263 Great Val Malvern PA 19355

Key Executives
CEO: Musunuri, Shankar
CFO: Breininger, Michael
COO: N/A
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures